Validation of a colistin plasma concentration breakpoint as a predictor of nephrotoxicity in patients treated with colistin methanesulfonate

详细信息    查看全文

• 作者：Juan P. Horcajada^a ; ^{jhorcajada@parcdesalutmar.cat} ; Luisa Sorlí ; ^a ; Sonia Luque^b ; Natividad Benito^c ; ^d ; ^e ; Concepció ; n Segura^f ; Nuria Campillo^b ; Milagro Montero^a ; Erika Esteve^a ; Beatriz Mirelis^g ; Virginia Pomar^c ; ^d ; ^e ; Jordi Cuquet^h ; Carmina Martí ; ^h ; Pau Garro^h ; Santiago Grau^b
• 关键词：Colistin ; Nephrotoxicity ; Risk factors ; Plasma concentration ; Therapeutic drug monitoring
• 刊名：International Journal of Antimicrobial Agents
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：48
• 期：6
• 页码：725-727
• 全文大小：205 K
• 卷排序：48

文摘

A steady-state colistin plasma concentration (Css) > 2.42 mg/L is an independent risk factor of nephrotoxicity. This has been validated in a prospective cohort of patients treated with colistin methanesulfonate. Nephrotoxicity was significantly more frequent and occurred earlier in patients with Css > 2.42 mg/L. Colistin has a narrow therapeutic window. Therapeutic drug monitoring is recommended in patients receiving colistin therapy.